

SUVEN Life Sciences Ltd



Press Release

Suven Income up by 35%, Spends 17% on R&D

Suven shares split from Rs 2 per share to Re. 1 per share and issues bonus shares in the ratio of 1:1

HYDERABAD, INDIA (Jan' 29, 2007) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced that the revenue and profit after tax **recorded a growth of 19%** for the quarter ended Dec 2006 compared to corresponding quarter of the previous year. The **sales stood at Rs. 3225 lacs increased from Rs. 2711 lacs** and the net profit after tax recorded at Rs. 383 lacs, increased from Rs. 321 lacs. The exports sales also recorded a growth of 21%.

The Company also posted impressive revenue of **Rs.8585** lacs for the 9 months ended Dec 2006 surpassing annual revenue recorded in previous year of Rs. 8301 (**recording a growth of 35%** compared to the corresponding previous period). The profit after tax (PAT) also increased by **35%** from **Rs.724** lacs to **Rs.876** lacs.

The Company's R&D cost for 9 months period stood at Rs. 1443 lacs, constituting 17% of the total revenue. During the quarter the Company also completed the merger process with Asian Clinical Trials Limited. The Board has recommended the issue of bonus shares at **1:1 ratio** and also considered splitting of the Rs. 2 per share to Rs. 1 per share.

Suven Life Sciences is a Hyderabad based Life Sciences Company a Collaborative Research Partner (CRP) in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade. Suven was awarded "Partner of Choice in Drug Discovery for CNS" by Frost & Sullivan in 2005.

Suven has presented the data of their NCE's for **Alzheimer's and Obesity**, SUVN 502, SUVN 504 and SUVN 507 at **Society for Neurosciences (SFN)** during Oct, 2006 at **Atlanta, USA**. So far eight global pharmaceutical majors have showed keen interest in collaborating for these molecules for further development.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

